How does MDIT's PB Ratio compare to its peers?

Insufficient data to calculate MDIT's Price-To-Book Ratio vs. peers for valuation analysis.

How does MDIT's PB Ratio compare vs other companies in the US Medical Equipment Industry?

Insufficient data to calculate MDIT's Price-To-Book Ratio vs. industry for valuation analysis.

What is MDIT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate MDIT's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of MDIT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate MDIT's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Medite Cancer Diagnostics (OTCPK:MDIT) - Stock Price, News & Analysis

MDIT Stock Overview

Operates as a medical technology company. More details

MDIT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Does not have a meaningful market cap ($85)

Latest financial reports are more than a year old

My Notes

Capture your thoughts, links and company narrative

Medite Cancer Diagnostics, Inc. Competitors

Motus GI Holdings

OTCPK:MOTS

US$719.0

ThermoGenesis Holdings

OTCPK:THMO

US$4.8k

BIMI Holdings

OTCPK:BIMI

US$1.4k

UpHealth

OTCPK:UPHL

US$3.8k

Price History & Performance

Summary of share price highs, lows and changes for Medite Cancer Diagnostics
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-100.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	MDIT	US Medical Equipment	US Market
7D	0%	-0.2%	0.2%
1Y	n/a	14.4%	23.1%

Return vs Industry: Insufficient data to determine how MDIT performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how MDIT performed against the US Market.

Price Volatility

Is MDIT's price volatile compared to industry and market?
MDIT volatility
MDIT Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	5.9%
10% most volatile stocks in US Market	18.3%
10% least volatile stocks in US Market	3.0%

Stable Share Price: MDIT's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine MDIT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	n/a	medite-group.com

Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning.

Medite Cancer Diagnostics, Inc. Fundamentals Summary

How do Medite Cancer Diagnostics's earnings and revenue compare to its market cap?
MDIT fundamental statistics
Market cap	US$85.00
Earnings (TTM)	-US$5.42m
Revenue (TTM)	US$8.13m

0.0x

P/S Ratio

0.0x

P/E Ratio

Is MDIT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MDIT income statement (TTM)
Revenue	US$8.13m
Cost of Revenue	US$6.21m
Gross Profit	US$1.93m
Other Expenses	US$7.35m
Earnings	-US$5.42m

Last Reported Earnings

Sep 30, 2018

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MDIT perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/02/12 04:37
End of Day Share Price	2024/12/17 00:00
Earnings	2018/09/30
Annual Earnings	2017/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Medite Cancer Diagnostics, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ajay Tandon	SeeThruEquity, LLC